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eart Failure
State of Brain Natriuretic Peptide
eficiency or Resistance or Both!*
orng H. Chen, MB, BCH, FACC
ochester, Minnesota
eart failure (HF) is a clinical syndrome associated with
rogressive cardiac, vascular, and renal dysfunction. Regard-
ess of the initial cause of the cardiac dysfunction, investi-
ations over the past 3 decades have demonstrated that
eurohormones play an important role in the complex
ultiorgan and cellular adaptations in HF (1). In endocri-
opathies, the 2 main pathophysiological mechanisms in-
lude: 1) excessive production of the hormone; or 2)
eficiency of the hormone or resistance to the hormone. In
F, it has been well established that excessive activation of
asoconstricting and pro-proliferative neurohumoral sys-
ems such as the adrenergic and the renin-angiotensin-
ldosterone have detrimental effects, and antagonizing these
See pages 1071 and 1079
ystems improved morbidity and mortality (2). However,
ith regard to the vasodilating and antiproliferative neuro-
umoral systems such as the natriuretic peptides, their
atho-physiological states in HF are more complicated. In
his issue of the Journal, 2 studies, one by Liang at el. (3) and
he other by Forfia et al. (4), suggest that HF may be a state
f combined deficiency of the active form of brain natri-
retic peptide (BNP) 1-32 and resistance to BNP 1-32.
his paradigm of combined deficiency and resistance to an
ndogenous hormone is similar to diabetes mellitus, where
here is insulin deficiency in type I diabetes mellitus and
nsulin resistance in type II diabetes mellitus.
Brain natriuretic peptide is mainly produced by the
ardiac myocytes and together with atrial natriuretic peptide
ANP) and C type natriuretic peptide play an important role
n cardiorenal homeostasis. Atrial natriuretic peptide and
NP bind to the natriuretic peptide-A receptor (NPR-A),
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ayo Clinic College of Medicine, Rochester, Minnesota. This research was sup-
orted by grants from the National Institutes of Health (PO1 HL 76611), MayoB
oundation, and the American Heart Association. The author has received research
rants from Scios Inc. James DeLemos, MD, served as Guest Editor for this article.hich, via 3=,5=-cyclic guanosine monophosphate (cGMP),
ediates natriuresis, vasodilatation, renin-inhibition, anti-
schemic, antimitogenesis, and positive lusitropism (5). C
ype natriuretic peptide lacks natriuretic actions, but pos-
esses vasodilating and growth-inhibiting actions via the
uanylyl cyclase-linked natriuretic peptide-B receptor
NPR-B). All 3 peptides are cleared by the natriuretic
eptide-C receptor (NPR-C) and degraded by the ectoen-
yme neutral endopeptidase 24.11 (NEP), both of which are
idely expressed in kidney, lung, and vascular wall.
Heart failure is a state of intense activation of BNP as
videnced by increased expression of the BNP mRNA in
oth the atrial and ventricle and increased plasma concen-
ration of immunoreactive BNP (6). Studies have demon-
trated that BNP plays an important role in maintaining
ardiorenal homeostasis in asymptomatic left ventricular
ysfunction (stage B HF) resulting in preservation of
odium and water balance despite left ventricular dysfunc-
ion (7). However, in severe symptomatic HF (stage C/D),
here is sodium and water retention associated with in-
reased systemic vascular resistance and high cardiac filling
ressures despite an extremely high plasma concentration of
mmunoreactive BNP. The cause for this discordance in
lasma immunoreactive BNP level and cardiorenal physiol-
gy in severe HF is multifactorial and complex.
In both experimental and human HF, investigations have
upported the hypothesis that the synthetic capacity of the
ardiac myocytes may be overwhelmed in severe HF relative to
he demands of the system, leading to a state of relative
eficiency. Indeed, Redfield et al. (8) demonstrated in
hronic severe experimental congestive HF, an impaired
apacity to release ANP in response to acute volume
xpansion with increases in atrial pressures (8). Volpe et al.
9) have also demonstrated an impaired release of ANP in
umans with dilated cardiomyopathy. Thus, a relative
eficiency may occur in chronic severe HF with biological
onsequences. Previous studies have reported that 2 major
olecular forms of BNP are present in the plasma of
atients with HF, a high molecular weight (HMW) form
nd low molecular weight (LMW) form. It has been
uggested that the HMW form is the pro-BNP hormone
nd the LMW form is the active BNP 1-32 (10). Shimizu
t al. (10) demonstrated that the HMW form was present at
imilar amounts to the LMW form in plasma from HF
atients. More importantly, using reverse-phase HPLC,
hey found very little detectable BNP 1-32 from the LMW
raction (10). Supporting these findings, Hawkridge et al.
11) failed to detect BNP 1-32, with mass spectroscopy
echniques in plasma from patients with severe HF and high
evels of immunoreactive BNP as measured by the Triage
oint of care assay (Biosite Inc., San Diego, California).
he study by Liang et al. (3) in this issue of the Journal
onfirms and extends previous studies unraveling another
iece of this complex puzzle. Using Western blot analysis of
NP immunoreactive species in HF plasma, they confirmed
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Editorial Comment March 13, 2007:1089–91hat the HMW form represents a significant percentage of
he total BNP immunoreactive material when compared
ith LMW BNP. They extended previous findings by
emonstrating that the HMW form is similar to pro-BNP
nd is glycosylated. Importantly, the authors demonstrated
hat recombinant pro-BNP exerted significantly less biolog-
cal activity as compared with BNP 1-32. Furthermore, the
riage and ADVIA Centaur (Bayer HealthCare, Tarry-
own, New York) BNP assays recognize both pro-BNP and
NP 1-32, while the Elecsys NT-pro-BNP assay (Roche
iagnostics, Basel, Switzerland) recognizes only the pro-
NP. These data, together with previous studies, support
he hypothesis that HF is a state of deficiency of active BNP
-32, thus accounting partially for the discrepancy between
he high immunoreactive BNP levels and the lack of
iological activity in severe HF. However, it has to be
ointed out that all these studies used plasma from patients
ith New York Heart Association functional class IV severe
F (stage D) and, therefore, cannot be extrapolated to all
atients with HF. Further studies are needed to determine
he molecular forms of BNP in patients with less severe HF
specially those with left ventricular dysfunction that do not
ave any symptoms (stage B HF).
Both human severe HF and animal models of severe HF
re characterized by an attenuated biological response to
ndogenous and exogenous natriuretic peptides (12). In-
eed, it has been suggested that the diminished response to
he cardiac natriuretic peptides play an important role in the
athophysiology of sodium retention and systemic and renal
asoconstriction observed in severe HF, thus contributing to
isease progression (13). These observations have led to the
oncept that there is the development of resistance to the
atriuretic peptides in severe HF. This concept is supported
y previous studies and reconfirmed by the study by Forfia
t al. (4) in this issue of the Journal, demonstrating that the
enal effects of exogenously administered BNP was attenu-
ted in experimental HF as compared with normal dogs.
he mechanisms for the development of resistance to
atriuretic peptide are multifactorial and include the follow-
ng: increased clearance by NEP or the clearance receptor,
own-regulation of receptor or post-receptor issues such as
ncreased activity of cGMP phosphodiesterase (PDE) V,
hich metabolizes cGMP (5). In vivo, studies have dem-
nstrated that cGMP PDE V inhibition markedly potenti-
tes the renal response to acute volume expansion and
ow-dose ANP, an effect that was attenuated by adminis-
ration of a monoclonal antibody directed against ANP
14). Supaporn et al. (15) have reported the increases in type
and type V cGMP PDE V in severe congestive HF,
hich, therefore, could mediate the decrease in cGMP
eneration to the natriuretic peptides in HF. In these
tudies in isolated glomeruli from kidneys of dogs with
evere HF, ANP-induced cGMP generation was attenuated
hen compared with control. We have recently reported
hat chronic PDE V inhibition in experimental severe HF
nhanced sodium excretion and renal cGMP generation inesponse to exogenous BNP (16). Thus, these studies
upport an important role for renal cGMP PDE V modu-
ation of the renal response to endogenous and exogenous
atriuretic peptides.
The current study by Forfia et al. (4) elegantly demon-
trated that there is an increase in PDE V activity in the
hole lung, pulmonary artery, aorta, inferior vena cava, and
idney of canine experimental HF. Importantly, they re-
orted that inhibition of PDE V with sildenafil (SIL) had
inimal effects on cardiovascular hemodynamics in normal
ogs, while in HF animals, SIL exerted similar cardiovas-
ular hemodynamic effects as BNP, and the combination of
NP and SIL was additive in reducing pulmonary pres-
ures. These findings suggest that the increased PDE V
ctivity in HF has physiological consequences as supported
y the fact that inhibition of PDE V in HF resulted in
avorable cardiovascular hemodynamics. The combination
f BNP and SIL did not improve the renal response in HF
nimals in the current study. This is in contrast with
revious reports and may be related to the fact that there
as a significant decrease in mean arterial blood pressure,
hich may have attenuated the renal effects. We have
ecently reported that non-hypotensive doses of BNP have
ifferential renal effects as compared with hypotensive doses
f BNP (17).
In summary, HF is a syndrome with complex neurohu-
oral activation and interactions. The authors of these 2
mportant reports have provided new insights into the
olecular forms of BNP and the resistance to BNP in HF.
hese studies support the conclusion that HF is both a state
f deficiency and resistance to the active BNP 1-32. Brain
atriuretic peptide is currently clinically used as both a
iomarker and a therapeutic agent in HF. To allow us to
ealize the full diagnostic and therapeutic potential of the
atriuretic peptides, continued investigations into the role
f the natriuretic peptides in the pathophysiology of the
rogression of HF from stage B to stage D are clearly
arranted.
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Ch, Cardiorenal Research Laboratory, Guggenheim 915, Mayo
linic and Foundation, 200 First Street SW, Rochester, Minne-
ota 55905. E-mail: chen.horng@mayo.edu.
EFERENCES
1. Francis GS, Benedict C, Johnstone DE, et al. Comparison of
neuroendocrine activation in patients with left ventricular dysfunction
with and without congestive heart failure. A substudy of the Studies Of
Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724–9.
2. The SOLVD Investigators. Effects of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart
failure. N Engl J Med 1991;325:293–302.
3. Liang F, O’Rear J, Schellenberger U, et al. Evidence for functional
heterogeneity of circulating B-type natriuretic peptide. J Am Coll
Cardiol 2007;49:1071–8.
4. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA.
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of
B-type natriuretic peptide and potentiates B-type natriuretic peptide
11
1
1
1
1
1
1
1091JACC Vol. 49, No. 10, 2007 Chen
March 13, 2007:1089–91 Editorial Commenteffects in failing but not normal canine heart. J Am Coll Cardiol
2007;49:1079–88.
5. Chen HH, Burnett JC, Jr. The natriuretic peptides in heart failure:
diagnostic and therapeutic potentials (review). Proc Assoc Am Physi-
cians 1999;111:406–16.
6. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and
ventricular expression of myocardial BNP during evolution of heart
failure. Am J Physiol 1998;274:H1684–9.
7. Stevens TL, Burnett JC Jr., Kinoshita M, Matsuda Y, Redfield MM.
A functional role for endogenous atrial natriuretic peptide in a canine
model of early left ventricular dysfunction. J Clin Invest 1995;95:
1101–8.
8. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus
LL, Burnett JC Jr. Failure of atrial natriuretic factor to increase with
volume expansion in acute and chronic congestive heart failure in the
dog. Circulation 1989;80:651–7.
9. Volpe M, Tritto C, De Luca N, et al. Failure of atrial natriuretic
peptide to increase with saline load in patients with dilated cardiomy-
opathy and mild heart failure. J Clin Invest 1993;88:1481–9.
0. Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain
natriuretic peptide in plasma. Clin Chim Acta 2002;316:129–35.
1. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A,
Burnett JC Jr., Muddiman DC. Quantitative mass spectral evidence
for the absence of circulating brain natriuretic peptide (BNP-32) insevere human heart failure. Proc Natl Acad Sci U S A 2005;102:
17442–7.
2. Chen HH, Schirger JA, Chau WL, et al. Renal response to acute
neutral endopeptidase inhibition in mild and severe experimental heart
failure. Circulation 1999;100:2443–8.
3. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B.
Mechanisms of renal hyporesponsiveness to ANP in heart failure.
Eur J Clin Invest 2003;33:769–78.
4. Wilkins MR, Settle SL, Needleman P. Augmentation of the natri-
uretic activity of exogenous and endogenous atriopeptin in rats by
inhibition of guanosine 3=,5=-cyclic monophosphate degradation.
J Clin Invest 1990;85:1274–9.
5. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP
response to agonists and enhanced glomerular cyclic 3=,5=-nucleotide
phosphodiesterase activities in experimental congestive heart failure.
Kidney Int 1996;50:1718–25.
6. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr.
Maximizing the renal cyclic 3=-5=-guanosine monophosphate system
with type V phosphodiesterase inhibition and exogenous natriuretic
peptide: a novel strategy to improve renal function in experimental
overt heart failure. J Am Soc Nephrol 2006;17:2742–7.
7. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive
low-dose nesiritide has differential renal effects compared with
standard-dose nesiritide in patients with acute decompensated heart
failure and renal dysfunction. J Am Coll Cardiol 2006;47:2334–5.
